Article ID Journal Published Year Pages File Type
8486001 Vaccine 2018 8 Pages PDF
Abstract
Light to moderate alcohol use does not negatively impact adherence or retention in phase I clinical trials. Based on these screening data and the low infection rate of participants during the trial period, the screening process for participation in HVTN phase 1 trials has largely been successful in enrolling and retaining individuals with lower risk profiles. Focusing on binge drinking and increased HIV/STI risk during risk reduction counseling may be warranted.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , ,